Previous 10 | Next 10 |
Arcturus Therapeutics (NASDAQ: ARCT) , which focuses on clinical-stage messenger RNA (mRNA) medicines, saw its shares rise 16% on Thursday. The stock closed at $35.52 on Wednesday, then opened at $38 today and rose to as high as $41.15 by midmorning. The stock has a 52-week high of ...
Arcturus Therapeutics (ARCT +13.3%) has added more than a tenth in value to record its sharpest intraday gain in four months after announcing preliminary data from its ongoing booster studies for messenger-RNA-based COVID-19 vaccine candidates, ARCT-154 and ARCT-165. In the booster cohort of ...
Gainers: Adagio Therapeutics (NASDAQ:ADGI) +68%, Calliditas Therapeutics (NASDAQ:CALT) +28%, Assertio (NASDAQ:ASRT) +17%, Aptose Biosciences (NASDAQ:APTO) +16%, Arcturus Therapeutics (NASDAQ:ARCT) +15%. Losers: uniQure (NASDAQ:QURE) -25%, Regi...
Preliminary data from ongoing clinical booster study of ARCT-154 (5 mcg) shows a 50-fold increase in neutralizing antibody geometric mean concentration against SARS-CoV-2 using a validated pseudovirus microneutralization (MNT) assay Additional data shows activity against sever...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...
Arcturus develops mRNA vaccines for covid-19. Other bigger players made the company almost irrelevant. Emerging variants of concern just may give the company a reason to exist. For further details see: Arcturus: Emerging Covid Variants May Provide A Raison D'êTre
Direxion Shares has launched the Direxion Nanotechnology ETF (NYSEARCA:TYNE), which provides exposure to stocks involved in the creation and or manipulation of matter at the molecular level. "Investors continue to seek exposure to disruptive industries, but one important area they may not yet...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2021 Earnings Conference Call November 8, 2021, 4:30 PM ET Company Participants Joseph Payne – President and CEO Deepankar Roy – Senior Director of Investor Relations Andy Sassine – CFO Pad Chivukula – CSO and COO Steve...
Arcturus Therapeutics (NASDAQ:ARCT): Q3 GAAP EPS of -$2.05 misses by $0.72. Revenue of $2.44M (+6.1% Y/Y) misses by $16.76M. Shares +2%. Press Release For further details see: Arcturus Therapeutics EPS misses by $0.72, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...